Finding. Human motor-neuron progenitors spend a long time poor in mitochondria, and they cannot become neurons unless pyruvate stops going to carboxylation and starts going through pyruvate dehydrogenase. Torregrosa-Munumer, Tyynismaa, Katajisto and colleagues walk human induced pluripotent stem cells to motor neurons with proteomics, metabolomics, and mitochondrial measurements at high temporal resolution. Early neurogenesis is a depletion state: less mitochondrial content, more fragmentation, lysosome-dependent turnover, lasting through the progenitor stage. Content comes back as the cells mature. At that same transition, pyruvate use flips from carboxylation toward PDH-dependent oxidation. Drug the partition, and human neuronal differentiation fails.
Why this paper matters
Every ALS, SMA, and mitochondrial-disease motor-neuron paper that starts from iPSCs has been missing this clock. If progenitors are supposed to be mitochondrially depleted, a "low mtDNA" readout at day 10 may be development, not disease. If PDH-ward pyruvate use is required to leave the progenitor state, a patient line that cannot make that flip will look like a differentiation failure and get discarded as a bad protocol. This preprint makes both mistakes harder to commit.
Cortical and hippocampal lineages already had remodeling stories. Motor neurons now have a human, multi-omic, functionally tested one. The functional test is the prize: pyruvate partitioning is not a correlative metabolomic wiggle. It is required.
What they actually measured
A differentiation time course with three stacked layers (proteome, metabolome, mitochondrial content/shape/turnover) plus pharmacology on pyruvate carboxylation versus PDH. Lysosome-dependent turnover is named; a specific mitophagy receptor is not. The abstract does not print the compound names.
How to read the score
Low 90s. Human motor-neuron mitochondria, a two-phase model, a required metabolic switch. Confidence is high for the in vitro sequence.
Caveats
A dish is not an embryo. Lysosomal turnover is not yet PINK1/Parkin or a named receptor here. Pharmacologic pyruvate tools can be dirty; the paper's claim is the switch, not a single clean drug.
What to do with it
If you differentiate human motor neurons for mitochondrial disease, align your days to this depletion-then-recovery curve before you call a line deficient. Pull the pyruvate-partition experiment and repeat it in ALS/SMA/POLG lines. Do not treat progenitor mitochondrial poverty as a pathology by default.